{"id":7399,"date":"2025-06-18T13:11:53","date_gmt":"2025-06-18T13:11:53","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7399"},"modified":"2025-06-18T13:11:54","modified_gmt":"2025-06-18T13:11:54","slug":"mira-pharmaceuticals-secures-key-publication-for-ketamir-2-a-next-gen-ketamine-analog","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/06\/18\/mira-pharmaceuticals-secures-key-publication-for-ketamir-2-a-next-gen-ketamine-analog\/","title":{"rendered":"MIRA Pharmaceuticals Secures Key Publication for Ketamir-2, a Next-Gen Ketamine Analog"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Peer-reviewed journal spotlights differentiated pharmacology and therapeutic promise for neuropathic pain<\/h4>\n\n\n\n<p>MIRA Pharmaceuticals (MIRA), a clinical-stage biotech firm focused on developing innovative treatments for neurologic, neuropsychiatric, and metabolic disorders, announced a significant milestone today: the first peer-reviewed manuscript detailing its lead drug candidate, Ketamir-2, has been accepted for publication in <em>Frontiers in Pharmacology<\/em>.<\/p>\n\n\n\n<p>Authored by Dr. Itzchak Angel, MIRA\u2019s Chief Scientific Advisor, the article\u2014titled <em>&#8220;KETAMIR-2, A NEW MOLECULAR ENTITY AND NOVEL KETAMINE ANALOG&#8221;<\/em>\u2014presents compelling preclinical data supporting the pharmacological uniqueness of Ketamir-2. Currently in an ongoing Phase 1 clinical trial for neuropathic pain, the compound is positioned as a next-generation central nervous system (CNS) therapeutic.<\/p>\n\n\n\n<p>The acceptance of the manuscript marks a key step in validating MIRA\u2019s approach to reengineering ketamine\u2019s therapeutic profile. Unlike traditional ketamine, Ketamir-2 was specifically designed to address its known limitations\u2014including poor oral bioavailability, dissociative side effects, and non-specific receptor activity.<\/p>\n\n\n\n<p>Publication in a respected, peer-reviewed journal not only underscores the scientific rigor behind MIRA\u2019s drug development program, but also provides third-party validation from independent experts. The company views this as a strong endorsement of Ketamir-2\u2019s differentiated pharmacology and its potential to offer a safer, more targeted treatment for patients suffering from chronic neuropathic pain.<\/p>\n\n\n\n<p>As MIRA continues its clinical development efforts, the scientific spotlight on Ketamir-2 may attract broader attention from the medical and investment communities, further advancing its mission to deliver transformative therapies for hard-to-treat CNS disorders.<\/p>\n\n\n\n<p>You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/06\/16\/amds-growth-engine-accelerates-as-piper-sandler-raises-price-target-to-140\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">AMD\u2019s Growth Engine Accelerates as Piper Sandler Raises Price Target to $140<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Peer-reviewed journal spotlights differentiated pharmacology and therapeutic promise for neuropathic pain MIRA Pharmaceuticals (MIRA), a clinical-stage biotech firm focused on developing innovative treatments for neurologic, neuropsychiatric, and metabolic disorders, announced a significant milestone today: the first peer-reviewed manuscript detailing its lead drug candidate, Ketamir-2, has been accepted for publication in Frontiers in Pharmacology. Authored by [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jnews-multi-image_gallery":[],"jnews_single_post":{"subtitle":"","format":"standard","video":"","gallery":"","source_name":"","source_url":"","via_name":"","via_url":"","override_template":"0","override":[{"template":"8","single_blog_custom":"","parallax":"1","fullscreen":"1","layout":"right-sidebar-narrow","sidebar":"author","second_sidebar":"single-right","sticky_sidebar":"1","share_position":"top","share_float_style":"share-monocrhome","show_share_counter":"0","show_view_counter":"0","show_featured":"1","show_post_meta":"1","show_post_author":"1","show_post_author_image":"0","show_post_date":"1","post_date_format":"default","post_date_format_custom":"Y\/m\/d","show_post_category":"1","show_post_reading_time":"1","post_reading_time_wpm":"300","show_zoom_button":"0","zoom_button_out_step":"2","zoom_button_in_step":"3","show_post_tag":"1","show_prev_next_post":"1","show_popup_post":"1","number_popup_post":"1","show_author_box":"0","show_post_related":"1","show_inline_post_related":"0"}],"override_image_size":"0","image_override":[{"single_post_thumbnail_size":"crop-500","single_post_gallery_size":"crop-500"}],"trending_post":"0","trending_post_position":"meta","trending_post_label":"Trending","sponsored_post":"0","sponsored_post_label":"Sponsored by","sponsored_post_name":"","sponsored_post_url":"","sponsored_post_logo_enable":"0","sponsored_post_logo":"","sponsored_post_desc":"","disable_ad":"0"},"jnews_primary_category":{"id":"","hide":""},"jnews_social_meta":{"fb_title":"","fb_description":"","fb_image":"","twitter_title":"","twitter_description":"","twitter_image":""},"jnews_override_counter":{"override_view_counter":"0","view_counter_number":"0","override_share_counter":"0","share_counter_number":"0","override_like_counter":"0","like_counter_number":"0","override_dislike_counter":"0","dislike_counter_number":"0"},"jnews_post_split":{"enable_post_split":"0","post_split":[{"template":"1","tag":"h2","numbering":"asc","mode":"normal","first":"0","enable_toc":"0","toc_type":"normal"}]}},"categories":[309,359],"tags":[421,511,416,418,417],"coauthors":[454],"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7399"}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7399"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7399\/revisions"}],"predecessor-version":[{"id":7400,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7399\/revisions\/7400"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7399"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}